Review of drug interactions with telaprevir and antiretrovirals

HCV infection is a major cause of mortality worldwide. HCV-related deaths also represent a leading cause of mortality in HIV-coinfected individuals. Telaprevir is an NS3/4A protease inhibitor approved for the treatment of chronic HCV genotype 1 infection in adults in combination with pegylated inter...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2013-01, Vol.18 (4), p.553-560
Main Authors: VAN HEESWIJK, Rolf P. G, BEUMONT, Maria, KAUFFMAN, Robert S, GARG, Varun
Format: Article
Language:English
Subjects:
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - therapeutic use
Biological and medical sciences
Coinfection
Drug Interactions
Drug Therapy, Combination
Hepacivirus - drug effects
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
HIV Infections - drug therapy
HIV Infections - virology
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Male
Medical sciences
Oligopeptides - therapeutic use
Pharmacology. Drug treatments
Protease Inhibitors - therapeutic use
Reverse Transcriptase Inhibitors - therapeutic use
Ritonavir - therapeutic use
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HCV infection is a major cause of mortality worldwide. HCV-related deaths also represent a leading cause of mortality in HIV-coinfected individuals. Telaprevir is an NS3/4A protease inhibitor approved for the treatment of chronic HCV genotype 1 infection in adults in combination with pegylated interferon and ribavirin. Telaprevir-based treatment has been shown to increase rates of sustained viral response in HCV genotype-1-monoinfected patients, and studies in HCV-HIV-coinfected patients are ongoing. Drug-drug interactions of telaprevir with antiretroviral drugs were investigated in a series of studies in healthy subjects. This review summarizes the results of interaction studies with low-dose ritonavir, ritonavir-boosted HIV protease inhibitors (atazanavir, darunavir, fosamprenavir and lopinavir), efavirenz, etravirine, rilpivirine, tenofovir disoproxil fumarate and raltegravir.
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP2527